Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade) [Seeking Alpha]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Seeking Alpha
On April 2, 2024, the EMA approved Reblozyl as a first-line treatment for anemia in certain patients with MDS. On March 14 of this year, Breyanzi was approved by the FDA to combat relapsed/refractory CLL and small lymphocytic lymphoma, which will help accelerate its sales growth. Analysts expect the company's revenue to continue growing over the next three years, reaching around $46.4 billion in 2025, representing a P/S ratio of 2.2x, suggesting it is trading at a discount to the healthcare sector. Bristol Myers Squibb Company ( NYSE: BMY ) is one of the largest pharmaceutical companies in the world, headquartered in Princeton, New Jersey. Investment thesis Since the publication of my last article in late 2023, the company's share price has continued to move sideways despite making significant progress in developing its pipeline of experimental drugs, as well as improving its financial position despite increased competition from generic versions of its blockbusters such as
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Jumo Health to Lead a Roundtable Discussion on Authenticity and the Patient Voice at the Annual Health Equity in Clinical Trials Congress [Yahoo! Finance]Yahoo! Finance
- Petauri™ Announces 2 Key Hires at Petauri Advisors [Yahoo! Finance]Yahoo! Finance
- Bristol Myers, Repertoire to develop tolerizing vaccines in multi-year pact [Seeking Alpha]Seeking Alpha
- Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases [Yahoo! Finance]Yahoo! Finance
- Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune DiseasesPR Newswire
BMY
Earnings
- 4/25/24 - Miss
BMY
Sec Filings
- 4/25/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/22/24 - Form DEFA14A
- BMY's page on the SEC website